Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2026)

Aquestive Therapeutics' Non-Current Debt history runs 10 years deep, the most recent figure standing at $45.0 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 33.35% year-over-year to $45.0 million in Q1 2026; TTM through Mar 2026 was $45.0 million, a 33.35% increase from a year earlier, with the FY2025 full-year figure at $27.5 million, down 15.33% from the prior year.
• Non-Current Debt advanced to $45.0 million in Q1 2026 per AQST's latest filing, from $27.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $47.7 million in Q1 2022 and bottomed at $17.5 million in Q2 2024.
• The 5-year median for Non-Current Debt is $33.7 million (2025), against an average of $35.4 million.
• Across the five-year window, Non-Current Debt slumped 55.16% in 2024 and soared 82.2% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $33.4 million in 2022, then dropped by 17.76% to $27.5 million in 2023, then increased by 18.15% to $32.5 million in 2024, then decreased by 15.33% to $27.5 million in 2025, then jumped by 63.52% to $45.0 million in 2026.
• Per Business Quant, the three latest AQST Non-Current Debt figures stand at $45.0 million (Q1 2026), $27.5 million (Q4 2025), and $29.9 million (Q3 2025).